EP Patent

EP3452039A4 — TREATMENT OF HAIR LOSS DISORDERS WITH DEUTERATED JAK INHIBITORS

Assigned to Sun Pharmaceutical Industries Inc · Expires 2019-12-25 · 6y expired

What this patent protects

Patent listed against deuruxolitinib-phosphate.

Drugs covered by this patent

deuruxolitinib-phosphate (DEURUXOLITINIB PHOSPHATE)

Patent Metadata

Patent number: EP3452039A4
Jurisdiction: EP
Classification: —
Expires: 2019-12-25
Drug substance claim: No
Drug product claim: No
Assignee: Sun Pharmaceutical Industries Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.